385
Views
14
CrossRef citations to date
0
Altmetric
Review

Clinical update on linezolid in the treatment of Gram-positive bacterial infections

&
Pages 87-102 | Published online: 25 Jun 2012

References

  • MoutonJWJanszARThe DUEL study:a multi-center in vitro evaluation of Linezolid compared with other antibiotics in The NetherlandsClin Microbiol Infect20017948649111678931
  • DraghiDCSheehanDJHoganPSahmDFIn vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance programAntimicrob Agents Chemother200549125024503216304168
  • MutnickAHBiedenbachDJTurnidgeJDJonesRNSpectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998–2000Diagn Microbiol Infect Dis2002431657312052631
  • JevittLASmithAJWilliamsPPRaneyPMMcGowanJEJrTenoverFCIn vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faeciumMicrob Drug Resist20039438939315000746
  • FlueggeKSupperSSiedlerABernerRAntibiotic susceptibility in neonatal invasive isolates of Streptococcus agalactiae in a 2-year nationwide surveillance study in GermanyAntimicrob Agents Chemother200448114444444615504878
  • JonesRNStilwellMGHoganPASheehanDJActivity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance ProgramAntimicrob Agents Chemother20075141491149317210770
  • BetriuCRedondoMPalauMLComparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococciAntimicrob Agents Chemother20004471838184110858339
  • Kosowska-ShickKSmithKBogdanovichTEdnieLMJonesRNAppelbaumPCActivity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominisAntimicrob Agents Chemother200650124191419417043120
  • ZhanelGGPalatnickLNicholKABellyouTLowDEHobanDJAntimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002Antimicrob Agents Chemother20034761867187412760860
  • FunkeGNietznikCMinimal inhibitory concentrations of linezolid against clinical isolates of coryneform bacteriaEur J Clin Microbiol Infect Dis200524961261416175358
  • KlareIKonstabelCWernerGAntimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional useJ Antimicrob Chemother200759590091217369278
  • BowersockTLSalmonSAPortisESMICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animalsAntimicrob Agents Chemother20004451367136910770781
  • Brown-ElliottBAWardSCCristCJMannLBWilsonRWWallaceRJJrIn vitro activities of linezolid against multiple Nocardia speciesAntimicrob Agents Chemother20014541295129711257051
  • AckermannGAdlerDRodloffACIn vitro activity of linezolid against Clostridium difficileJ Antimicrob Chemother200351374374512615885
  • BainesSDNoelARHuscroftGSEvaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut modelJ Antimicrob Chemother20116671537154621504940
  • DaeschleinGHoehneCAssadianOIn vitro activity of linezolid against clinical isolates of Fusobacterium sppJ Antimicrob Chemother200658478979316905529
  • CitronDMMerriamCVTyrrellKLWarrenYAFernandezHGoldsteinEJIn vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteriaAntimicrob Agents Chemother20034772334233812821492
  • MolitorisDVäisänenMLBolañosMFinegoldSMIn vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolatesAntimicrob Agents Chemother20065051887188916641470
  • SmithAJHallVThakkerBGemmellCGAntimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial agentsJ Antimicrob Chemother200556240740915972310
  • Brown-ElliottBACristCJMannLBWilsonRWWallaceRJJrIn vitro activity of linezolid against slowly growing nontuberculous MycobacteriaAntimicrob Agents Chemother20034751736173812709349
  • YangSCHsuehPRLaiHCHigh prevalence of antimicrobial resistance in rapidly growing mycobacteria in TaiwanAntimicrob Agents Chemother20034761958196212760874
  • ShinabargerDMechanism of action of the oxazolidinone antibacterial agentsExpert Opin Investig Drugs19998811951202
  • ColcaJRMcDonaldWGWaldonDJCrosslinking in the living cell locates the site of action of oxazolidinone antibioticsJ Biol Chem200327824219722197912690106
  • LeachKLSwaneySMColcaJRThe site of action of oxazolidinone antibiotics in living bacteria and in human mitochondriaMol Cell200726339340217499045
  • JonesRNKohnoSOnoYRossJEYanagiharaKZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countriesDiagn Microbiol Infect Dis200964219120119500528
  • FarrellDJMendesRERossJEJonesRNLinezolid surveillance program results for 2008 (LEADER Program for 2008)Diagn Microbiol Infect Dis200965439240319913682
  • RossJEFarrellDJMendesRESaderHSJonesRNEight-year (2002–2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countriesJ Chemother2011232717621571621
  • ZurenkoGToddWMHafkinBADevelopment of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid (abstract)Proceedings of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)San Francisco, CASeptember 26–29, 1999
  • GonzalesRDSchreckenbergerPCGrahamMBKelkarSDenBestenKQuinnJPInfections due to vancomycin-resistant Enterococcus faecium resistant to linezolidLancet20013579263117911323048
  • TsiodrasSGoldHSSakoulasGLinezolid resistance in a clinical isolate of Staphylococcus aureusLancet2001358927720720811476839
  • PotoskiBAAdamsJClarkeLEpidemiological profile of linezolid-resistant coagulase-negative staphylococciClin Infect Dis200643216517116779742
  • JonesRNFritscheTRSaderHSRossJEZyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countriesDiagn Microbiol Infect Dis200759219920917908617
  • MutnickAHEnneVJonesRNLinezolid resistance since 2001: SENTRY Antimicrobial Surveillance ProgramAnn Pharmacother200337676977412773059
  • MekaVGGoldHSAntimicrobial resistance to linezolidClin Infect Dis20043971010101515472854
  • KellySCollinsJMaguireMAn outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unitJ Antimicrob Chemother200861490190718272512
  • PrystowskyJSiddiquiFChosayJResistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococciAntimicrob Agents Chemother20014572154215611408243
  • FarrellDJMendesRERossJESaderHSJonesRNLEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United StatesAntimicrob Agents Chemother20115583684369021670176
  • KolaAKirschnerPGohrbandtBAn infection with linezolid-resistant S. aureus in a patient with left ventricular assist systemScand J Infect Dis200739546346517464873
  • DobbsTEPatelMWaitesKBMoserSAStammAMHoesleyCJNosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical centerJ Clin Microbiol20064493368337016954275
  • MillerKO’NeillAJWilcoxMHInghamEChopraIDelayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agentsAntimicrob Agents Chemother20085261940194418378719
  • KehrenbergCSchwarzSJacobsenLHansenLHVesterBA new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503Mol Microbiol20055741064107316091044
  • TohSMXiongLAriasCAAcquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolidMol Microbiol20076461506151417555436
  • WelshmanIRSissonTAJungbluthGLStalkerDJHopkinsNKLinezolid absolute bioavailability and the effect of food on oral bioavailabilityBiopharm Drug Dispos2001223919711745911
  • GeeTEllisRMarshallGAndrewsJAshbyJWiseRPharmacokinetics and tissue penetration of linezolid following multiple oral dosesAntimicrob Agents Chemother20014561843184611353635
  • SlatterJGStalkerDJFeenstraKLPharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjectsDrug Metab Dispos20012981136114511454733
  • StalkerDJJungbluthGLClinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterialClin Pharmacokinet200342131129114014531724
  • GrunderGZysset-AschmannYVollenweiderFMaierTKrähenbühlSDreweJLack of pharmacokinetic interaction between linezolid and antacid in healthy volunteersAntimicrob Agents Chemother2006501687216377669
  • KeelRASchaeftleinAKloftCPharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosisAntimicrob Agents Chemother20115573393339821518837
  • StalkerDJJungbluthGLHopkinsNKBattsDHPharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic in healthy volunteersJ Antimicrob Chemother20035151239124612668582
  • MacGowanAPPharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infectionsJ Antimicrob Chemother200351Suppl 2ii172512730139
  • MeagherAKForrestARaynerCRBirminghamMCSchentagJJPopulation pharmacokinetics of linezolid in patients treated in a compassionate-use programAntimicrob Agents Chemother200347254855312543657
  • AdembriCFallaniSCassettaMILinezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusionInt J Antimicrob Agents200831212212918055183
  • SissonTLJungbluthGLHopkinsNKAge and sex effects on the pharmacokinetics of linezolidEur J Clin Pharmacol2002571179379711868801
  • ClemettDMarkhamALinezolidDrugs200059481582710804037
  • DehghanyarPBürgerCZeitlingerMPenetration of linezolid into soft tissues of healthy volunteers after single and multiple dosesAntimicrob Agents Chemother20054962367237115917535
  • LoveringAMZhangJBannisterGCPenetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacementJ Antimicrob Chemother200250737712096009
  • Kutscha-LissbergFHeblerUMuhrGKöllerMLinezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococciAntimicrob Agents Chemother200347123964396614638510
  • BoselliEBreilhDRimmeléTPharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumoniaCrit Care Med20053371529153316003058
  • HoneybourneDTobinCJevonsGAndrewsJWiseRIntrapulmonary penetration of linezolidAntimicrob Chemother200351614311434
  • ConteJEJrGoldenJAKippsJZurlindenEIntrapulmonary pharmacokinetics of linezolidAntimicrob Agents Chemother20024651475148011959585
  • TsonaAMetallidisSForoglouNLinezolid penetration into cerebrospinal fluid and brain tissueJ Chemother2010221171920227987
  • BoakLMLiJSpelmanDdu CrosPNationRLRaynerCRSuccessful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitisAnn Pharmacother2006407–81451145516772405
  • MyrianthefsPMarkantonisSLVlachosKSerum and Cerebrospinal Fluid Concentrations of Linezolid in Neurosurgical PatientsAntimicrob Agents Chemother200650123971397616982782
  • BeerREngelhardtKWPfauslerBPharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drainsAntimicrob Agents Chemother20075137938217043116
  • ViaggiBPaoloADDanesiRLinezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokineticsScand J Infect Dis201143972172721585240
  • PrydalJIJenkinsDRLoveringAWattsAThe pharmacokinetics of linezolid in the non-inflamed human eyeBr J Ophthalmol200589111418141916234443
  • VázquezEGMensaJLópezYPenetration of linezolid into the anterior chamber (aqueous humor) of the human eye after intravenous administrationAntimicrob Agents Chemother200448267067214742235
  • BuergerCPlockNDehghanyarPJoukhadarCKloftCPharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysisAntimicrob Agents Chemother20065072455246316801426
  • RaoGGStegerATobinCMlinezolid levels in pancreatic secretionsJ Antimicrob Chemother200148693193211733483
  • DePestelDDPeloquinCACarverPLPeritoneal dialysis fluid concentrations of linezolid in the treatment of vancomycin-resistant Enterococcus faecium peritonitisPharmacotherapy200323101322132614594349
  • DehghanyarPBürgerCZeitlingerMPenetration of linezolid into soft tissues of healthy volunteers after single and multiple dosesAntimicrob Agents Chemother20054962367237115917535
  • SagirliOOnalATokerSOztunçADetermination of linezolid in human breast milk by high-performance liquid chromatography with ultraviolet detectionJ AOAC Int20099261658166220166583
  • WilcoxMHKitePMillsKSugdenSIn situ measurement of linezolid and vancomycin concentrations in intravascular catheter-associated biofilmJ Antimicrob Chemother200147217117511157901
  • WiederholdNPCoyleEARaadIIPrinceRALewisREAntibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of Gram-positive catheter-related bacteraemiaJ Antimicrob Chemother200555579279515814598
  • BaystonRNuradeenBAshrafWFreemanBJAntibiotics for the eradication of Propionibacterium acnes biofilms in surgical infectionJ Antimicrob Chemother20076061298130117959732
  • LeiteBGomesFTeixeiraPSouzaCPizzolittoEOliveiraRIn vitro activity of daptomycin, linezolid and rifampicin on Staphylococcus epidermidis biofilmsCurr Microbiol201163331331721761219
  • BaystonRUllasGAshrafWThe action of linezolid or vancomycin on biofilms in ventriculoperitoneal shunts in vitroAntimicrob Agents Chemother2012 [Epub ahead of print.]
  • HolmbergAMörgelinMRasmussenMEffectiveness of ciprofloxacin or linezolid in combination with rifampicin against Enterococcus faecalis in biofilmsJ Antimicrob Chemother201267243343922110086
  • SandoeJAWysomeJWestAPHeritageJWilcoxMHMeasurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilmsJ Antimicrob Chemother200657476777016464896
  • BrierMEStalkerDJAronoffGRPharmacokinetics of linezolid in subjects with renal dysfunctionAntimicrob Agents Chemother20034792775278012936973
  • HendershotPEJungbluthGLCammarataSKHopkinsNJPharmacokinetics of linezolid in patients with liver diseaseJ Antimicrob Chemother199944Suppl A55
  • FiaccadoriEMaggioreURotelliCRemoval of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failureCrit Care Med200432122437244215599148
  • MeyerBKornekGVNikfardjamMMultiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltrationJ Antimicrob Chemother200556117217915905303
  • TrotmanRLWilliamsonJCShoemakerDMSalzerWLAntibiotic dosing in critically ill adult patients receiving continuous renal replacement therapyClin Infect Dis20054181159116616163635
  • KearnsGLAbdel-RahmanSMBlumerJLSingle dose pharmacokinetics of linezolid in infants and childrenPediatr Infect Dis J200019121178118411144380
  • WiseRAndrewsJMBoswellFJAshbyJPThe in-vitro activity of linezolid (U-100766) and tentative breakpointsJ Antimicrob Chemother199842672172810052894
  • BowkerKEWoottonMHoltHAMacGowanAPIn vitro activity of linezolid against Gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis patientsJ Antimicrob Chemother200249357858011864965
  • ZurenkoGEYagiBHSchaadtRDIn vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agentsAntimicrob Agents Chemother19964048398458849237
  • RybakMJCappellettyDMMoldovanTAeschlimannJRKaatzGWComparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faeciumAntimicrob Agents Chemother19984237217249517963
  • WilcoxMNathwaniDDrydenMLinezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infectionsJ Antimicrob Chemother200453233534414729745
  • WilcoxMHTackKJBouzaEComplicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 studyClin Infect Dis200948220321219072714
  • FalagasMESiemposIIVardakasKZLinezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trialsLancet Infect Dis200881536618156089
  • BeibeiLYunCMengliCNanBXuhongYRuiWLinezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trialsInt J Antimicrob Agents201035131219900794
  • JangHCKimSHKimKHSalvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenemClin Infect Dis200949339540119569970
  • JaureguiLEBabazadehSSeltzerERandomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infectionsClin Infect Dis200541101407141516231250
  • WeigeltJItaniKStevensDLauWDrydenMKnirschCLinezolid CSSTI Study GroupLinezolid versus vancomycin in treatment of complicated skin and soft tissue infectionsAntimicrob Agents Chemother20054962260226615917519
  • StevensDLSmithLGBrussJBRandomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infectionsAntimicrob Agents Chemother200044123408341311083648
  • BounthavongMHsuDIEfficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysisCurr Med Res Opin201026240742120001574
  • SaroglouMTryfonSIsmailosGPharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusionJ Inflamm (Lond)201072220482752
  • San PedroGSCammarataSKOliphantTHTodiscoTLinezolid Community-Acquired Pneumonia Study GroupLinezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumoniaScand J Infect Dis2002341072072812477321
  • WalkeyAJO’DonnellMRWienerRSLinezolid versus glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trialsChest201113951148115520864609
  • WunderinkRGNiedermanMSKollefMHLinezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled studyClin Infect Dis201254562162922247123
  • RanaBButcherIGrigorisPMurnaghanCSeatonRATobinCMLinezolid penetration into osteo-articular tissuesJ Antimicrob Chemother200250574775012407135
  • HowdenBPWardPBCharlesPGTreatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibilityClin Infect Dis200438452152814765345
  • AneziokoroCOCannonJPPachuckiCTLentinoJRThe effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitisJ Chemother200517664365016433195
  • RaynerCRBaddourLMBirminghamMCNordenCMeagherAKSchentagJJLinezolid in the treatment of osteomyelitis: results of compassionate use experienceInfection200432181415007736
  • DaileyCFDileto-FangCLBuchananLVEfficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother20014582304230811451689
  • PatelRRouseMSPiperKESteckelbergJMLinezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditisAntimicrob Agents Chemother200145262162311158767
  • MunozPRodríguez-CreixémsMMorenoMMarínMRamalloVBouzaEGAME Study GroupLinezolid therapy for infective endocarditisClin Microbiol Infect200713221121517328738
  • TsigrelisCSinghKVCoutinhoTDMurrayBEBaddourLMVancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factorsJ Clin Microbiol200745263163517182759
  • CornePMarchandinHMaciaJCJonquetOTreatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolidScand J Infect Dis20053711–1294694916308242
  • FalagasMEMantaKGNtzioraFVardakasKZLinezolid for the treatment of patients with endocarditis: a systematic review of the published evidenceJ Antimicrob Chemother200658227328016735427
  • JacquelineCAsserayNBatardEIn vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureusInt J Antimicrob Agents200424439339615380267
  • NagashimaGOkamotoNOkudaMEffect of linezolid against postneurosurgical meningitis caused by methicillin-resistant Staphylococcus epidermidis: case reportJ Infect Chemother200814214715018622679
  • KruegerWAKottlerBWillBEHeiningerAGuggenbergerHUnertlKETreatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolidJ Clin Microbiol200442292993214766894
  • CastroPSorianoAEscrichCVillalbaGSarasaMMensaJLinezolid treatment of ventriculoperitoneal shunt infection without implant removalEur J Clin Microbiol Infect Dis200524960360616187055
  • TsujiYHirakiYMatsumotoKPharmacokinetics and protein binding of linezolid in cerebrospinal fluid and serum in a case of post-neurosurgical bacterial meningitisScand J Infect Dis20114311–1298298521851332
  • ZeanaCKubinCJDella-LattaPHammerSMVancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literatureClin Infect Dis200133447748211462183
  • FaellaFPaglianoPFuscoUAttanasioVConteMCombined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strainsClin Microbiol Infect200612439139416524418
  • RamírezPSahuquilloJMCortésCKotPBonastreJMLinezolid as rescue therapy for pneumococcal meningitisIntensive Care Med200733592492517431583
  • LeitiOGrossJWTuazonCUTreatment of brain abscess caused by Listeria monocytogenes in a patient with allergy to penicillin and trimethoprim-sulfamethoxazoleClin Infect Dis200540690790815736033
  • ViganòSMEdefontiAFerraressoMSuccessful medical treatment of multiple brain abscesses due to Nocardia farcinica in a paediatric renal transplant recipientPediatr Nephrol20052081186118815947983
  • JaksicBMartinelliGPerez-OteyzaJHartmanCSLeonardLBTackKJEfficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancerClin Infect Dis200642559760716447103
  • NanniniECKeatingMBinstockPSamonisGKontoyiannisDPSuccessful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquineJ Infect200244320120312099753
  • KyleSDPorterWMMycobacterium chelonae infection successfully treated with oral clarithromycin and linezolidBr J Dermatol20041515110115541095
  • NtzioraFFalagasMELinezolid for the treatment of patients with mycobacterial infections a systematic reviewInt J Tuberc Lung Dis200711660661117519090
  • RubinsteinECammarataSOliphantTWunderinkRLinezolid Nosocomial Pneumonia Study GroupLinezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter studyClin Infect Dis200132340241211170948
  • StevensDLHerrDLampirisHHuntJLBattsDHHafkinBLinezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infectionsClin Infect Dis200234111481149012015695
  • RubinsteinEIsturizRStandifordHCWorldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studiesAntimicrob Agents Chemother20034761824183112760854
  • KaplanSLDevilleJGYogevRLinezolid versus vancomycin for treatment of resistant Gram-positive infections in childrenPediatr Infect Dis J200322867768612913766
  • FalagasMEVardakasKZBenefit-risk assessment of linezolid for serious gram-positive bacterial infectionsDrug Saf200831975376818707190
  • CawleyMJLipkaOIntravenous linezolid administered orally: a novel desensitization strategyPharmacotherapy200626456356816553517
  • BishopEMelvaniSHowdenBPCharlesPGGraysonMLGood clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patientsAntimicrob Agents Chemother20065041599160216569895
  • KelleyWReshBGoldenbergG, Linezolid-induced purpuric medication reactionJ Cutan Pathol200936779379519519611
  • EspositoLKamarNGuilbeau-FrugierCMehrenbergerMModestoARostaingLLinezolid-induced interstitial nephritis in a kidney-transplant patientClin Nephrol200768532732918044266
  • SavardSDesmeulesSRiopelJAgharaziiMLinezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndromeAm J Kidney Dis2009546e17e2019733945
  • ApodacaAARakitaRMLinezolid-induced lactic acidosisN Engl J Med2003348868712510056
  • SuECrowleyKCarcilloJAMichaelsMGLinezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in childrenPediatr Infect Dis J201130980480621852764
  • ScottonPFuserRTorresanSEarly linezolid-associated lactic acidosis in a patient treated for tuberculous spondylodiscitisInfection200836438738818642110
  • ContouDFichetJGrimaldiDCariouAEarly life-threatening lactic acidosis following a single infusion of linezolidInt J Antimicrob Agents2011381848521482079
  • PalenzuelaLHahnNMNelsonRPJrDoes linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?Clin Infect Dis20054012e113e11615909253
  • GarrabouGSorianoALópezSReversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemiaAntimicrob Agents Chemother200751396296717194826
  • CarsonJCerdaJChaeJHHiranoMMaggiorePSevere lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphismPharmacotherapy200727577177417461714
  • FrenchGSafety and tolerability of linezolidJ Antimicrob Chemother200351Suppl 2ii455312730142
  • MonsonTSchichmanSAZentCSLinezolid-induced pure red blood cell aplasiaClin Infect Dis2002353E29E3112115113
  • AttassiKHershbergerEAlamRZervosMJThrombocytopenia associated with linezolid therapyClin Infect Dis200234569569811803505
  • GersonSLKaplanSLBrussJBHematologic effects of linezolid: summary of clinical experienceAntimicrob Agents Chemother20024682723272612121967
  • NasrawaySAShorrAFKuterDJO’GradyNLeVHCammarataSKLinezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin useClin Infect Dis200337121609161614689341
  • WeigeltJItaniKStevensDLauWDrydenMKnirschCLinezolid CSSTI Study GroupLinezolid versus vancomycin in treatment of complicated skin and soft tissue infectionsAntimicrob Agents Chemother20054962260226615917519
  • BernsteinWBTrottaRFRectorJTTjadenJABarileAJMechanisms for linezolid-induced anemia and thrombocytopeniaAnn Pharmacother200337451752012659607
  • OrrickJJJohnsTJanelleJRamphalRThrombocytopenia secondary to linezolid administration: what is the risk?Clin Infect Dis200235334834912115111
  • BirminghamMCRaynerCRMeagherAKFlavinSMBattsDHSchentagJJLinezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use programClin Infect Dis200336215916812522747
  • KuterDJTillotsonGSHematologic effects of antimicrobials: focus on the oxazolidinone linezolidPharmacotherapy200181010101311718489
  • LinYHWuVCTsaiIJHigh frequency of linezolid-associated thrombocytopenia among patients with renal insufficiencyInt J Antimicrob Agents200628434535116935472
  • HirakiYTsujiYMatsumotoKMoritaKKamimuraHKarubeYInfluence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobinAm J Med Sci2011342645646021681075
  • TsujiYHirakiYMatsumotoKThrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunctionJ Infect Chemother2011171707520582446
  • CohenNMihuCNSeoSKHematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantationBiol Blood Marrow Transplant200915101337134119747643
  • De BusLDepuydtPLibbrechtLSevere drug-induced liver injury associated with prolonged use of linezolidJ Med Toxicol20106332232620358416
  • BresslerAMZimmerSMGilmoreJLSomaniJPeripheral neuropathy associated with prolonged use of linezolidLancet Infect Dis20044852853115288827
  • LegoutLSennevilleEGomelJJYazdanpanahYMoutonYLinezolid-induced neuropathyClin Infect Dis200438576776814986270
  • RuckerJCHamiltonSRBardensteinDIsadaCMLeeMSLinezolid-associated toxic optic neuropathyNeurology200666459559816505322
  • JavaheriMKhuranaRNO’hearnTMLaiMMSadunAALinezolid-induced optic neuropathy: a mitochondrial disorder?Br J Ophthalmol200791111111517179125
  • JoshiLTaylorSRLargeOYacoubSLightmanSA case of optic neuropathy after short-term linezolid use in a patient with acute lymphocytic leukemiaClin Infect Dis2009487e73e7419231981
  • ThaiXCBruno-MurthaLABell’s palsy associated with linezolid therapy: case report and review of neuropathic adverse eventsPharmacotherapy20062681183118916863496
  • WynaldaMAHauerMJWienkersLCOxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomesDrug Metab Dispos20002891014101710950842
  • HendershotPEAntalEJWelshmanIRBattsDHHopkinsNKLinezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBrJ Clin Pharmacol200141556357211361053
  • WigenCLGoetzMBSerotonin syndrome and linezolidClin Infect Dis200234121651165212032904
  • BergeronLBouléMPerreaultSSerotonin toxicity associated with concomitant use of linezolidAnn Pharmacother200539595696115827071
  • HuangVGortneyJSRisk of serotonin syndrome with concomitant administration of linezolid and serotonin agonistsPharmacotherapy200626121784179317125439
  • ButterfieldJMLawrenceKRReismanAHuangDBThompsonCALodiseTPComparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial dataJ Antimicrob Chemother201267249450222139199
  • LawrenceKRAdraMGillmanPKSerotonin toxicity associated with the use of linezolid: a review of postmarketing dataClin Infect Dis200642111578158316652315
  • BounthavongMZargarzadehAHsuDIVannessDJCost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesisValue Health201114563163921839399
  • SchürmannDSorensenSVDe CockEDuttaguptaSReschACost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in GermanyEur J Health Econ2009101657918437437
  • De CockEKruegerWASorensenSCost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in GermanyInfection200937212313219277465
  • PatanwalaAEErstadBLNixDECost-effectiveness of linezolid and vancomycin in the treatment of surgical site infectionsCurr Med Res Opin200723118519317257479